Bioequivalence Studies for Two Different Strengths of Montelukast in Healthy Volunteers: 10 mg Film-coated Tablets and 5 mg Chewable Tablets

Abstract

In order to assess the bioequivalence of 2 different formulations of montelukast, a pivotal trial for the montelukast 10 mg film-coated tablets formulation and a pivotal trial for the montelukast 5 mg chewable tablets formulation were conducted.

For the 10 mg study, 34 healthy subjects were enrolled in a single centre, randomised, single-dose, open-label, 2-way crossover study, with a minimum washout period of 7 days, while for the 5 mg study, 42 healthy subjects were included in another study with a similar design. For both studies, plasma samples were collected up to 24 h post-dosing and drug levels were determined by reverse liquid chromatography and detected by tandem mass spectrometry detection.

Pharmacokinetic parameters used for bioequivalence assessment, area under the concentration-time curve from time zero to time of last non-zero concentration (AUC_0–t) and from time zero to infinity (AUC_0–inf) and maximum observed concentration (C_max), were determined from the drug concentration data using non-compartmental analysis.

In the 10 mg study, the 90% confidence intervals obtained by analysis of variance were 99.62–120.51% for C_max, 102.25–117.37% for AUC_0–t and 101.96–116.67% for AUC_0–inf, which were within the predefined acceptable range of 80.00–125.00%.

In the 5 mg study, the 90% confidence intervals were 91.14–98.46% for C_max, 93.02–98.42% for AUC_0–t and 93.09–98.63% for AUC_0–inf, which were within the predefined acceptable range of 80.00–125.00%.

Bioequivalence between formulations was concluded both in terms of rate and extent of absorption for both strengths.

Key words

montelukast - Bioequivalence - AUC - C_max - CAS number 158966-92-8

• References

• 1 Amlani S, Nadarajah T, McIvor RA. Montelukast for the treatment of asthma in the adult population. Exper Opin Pharmacother 2011; 12: 2119-2128
• 2 Summary of Product Characteristics – Singulair 10 mg Tablets, 2012
• 3 Summary of Product Characteristics – Singulair 5 mg Chewable Tablets, 2012
• 4 EMA, European Medicines Agency Guideline for the investigation of bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1/Corr**, 2010
• 5 ICH Topic E6 (R1) Guideline for good clinical practice. Note for guidance on good clinical practice. CPMP/ICH/135795. London 2002: 1-59
• 6 McKinnon RA, Evans AM. Cytochrome P450, 2. Pharmacogenetics. Aust J Hosp Pharm 2000; 30: 102-105
• 7 Sripalakit P, Maphanta S, Saraphanchotiwitthaya A. Bioequivalence study of two generic formulations of 10 mg montelukast tablets in healthy Thai male volunteers. International Journal of Clinical Pharmacology and Therapeutics 2010; 48: 628-632
• 8 Kim HT, Song Y-K, Lee SD et al. Relative bioavailability of two 5-mg Montelukast sodium chewable tablets: A single dose, randomized, open-label, 2-period crossover comparison in healthy adult male volunteers. Arzneimittelforschung 2012; 62: 123-127
• 9 Zhao JJ, Rogers JD, Holland SD et al. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharmaceutics & Drug Disposition 1997; 18: 769-777